NASDAQ:BMRN - US09061G1013 - Common Stock
The current stock price of BMRN is 57.77 USD. In the past month the price decreased by -2.84%. In the past year, price decreased by -31.29%.
Symbol | Company Name | TA | FA | PE | Market Cap |
---|---|---|---|---|---|
ABBV | ABBVIE INC | 20.07 | 375.50B | ||
AMGN | AMGEN INC | 13.01 | 152.70B | ||
GILD | GILEAD SCIENCES INC | 14.86 | 142.76B | ||
VRTX | VERTEX PHARMACEUTICALS INC | 23.38 | 101.56B | ||
REGN | REGENERON PHARMACEUTICALS | 12.56 | 60.77B | ||
ALNY | ALNYLAM PHARMACEUTICALS INC | N/A | 59.25B | ||
ARGX | ARGENX SE - ADR | 80.99 | 45.95B | ||
ONC | BEONE MEDICINES LTD-ADR | 6.89 | 40.63B | ||
INSM | INSMED INC | N/A | 30.67B | ||
BNTX | BIONTECH SE-ADR | N/A | 27.03B | ||
NTRA | NATERA INC | N/A | 23.06B | ||
BIIB | BIOGEN INC | 8.79 | 20.62B |
BioMarin Pharmaceutical, Inc. engages in the development and commercialization of therapies for people with serious and life-threatening rare diseases and medical conditions. The company is headquartered in San Rafael California, California and currently employs 3,040 full-time employees. The firm has eight commercial therapies and a clinical and preclinical pipeline. Its commercial products include Vimizim (elosulfase alpha), Naglazyme (galsulfase), Palynziq (pegvaliase-pqpz), Brineura (cerliponase alfa), Aldurazyme (laronidase), Roctavian (valoctocogene roxaparvovec), Kuvan (sapropterin dihydrochloride), and Voxzogo (vosoritide). Vimizim is an enzyme replacement therapy for the treatment of MPS IVA, a lysosomal storage disorder. The Roctavian is an adeno-associated virus (AAV5) vector gene therapy designed to restore factor VIII plasma concentrations in patients with severe hemophilia A. Its key clinical programs include Vosoritide, BMN 333, BMN 390, BMN 351, BMN 349, and INZ-701. Its late-stage enzyme replacement therapy, INZ-701, is being developed for the treatment of ENPP1 deficiency.
BIOMARIN PHARMACEUTICAL INC
770 Lindaro Street
San Rafael California CALIFORNIA 94901 US
CEO: Jean-Jacques Bienaime
Employees: 3040
Phone: 14155066700
The current stock price of BMRN is 57.77 USD. The price increased by 1.8% in the last trading session.
The exchange symbol of BIOMARIN PHARMACEUTICAL INC is BMRN and it is listed on the Nasdaq exchange.
BMRN stock is listed on the Nasdaq exchange.
35 analysts have analysed BMRN and the average price target is 98.8 USD. This implies a price increase of 71.01% is expected in the next year compared to the current price of 57.77. Check the BIOMARIN PHARMACEUTICAL INC stock analysts ratings, price target forecast and up-and down grades for more detailed information.
BIOMARIN PHARMACEUTICAL INC (BMRN) has a market capitalization of 11.09B USD. This makes BMRN a Large Cap stock.
BIOMARIN PHARMACEUTICAL INC (BMRN) currently has 3040 employees.
BIOMARIN PHARMACEUTICAL INC (BMRN) has a support level at 56.56 and a resistance level at 57.87. Check the full technical report for a detailed analysis of BMRN support and resistance levels.
The Revenue of BIOMARIN PHARMACEUTICAL INC (BMRN) is expected to grow by 12.45% in the next year. Check the estimates tab for more information on the BMRN EPS, Sales, EBIT and EBITDA future analyst estimates.
There is no straightforward answer here. It depends on your investment strategy as different types of investors will look at different aspects. In any case it is important to make an informed decision and these pages can help you forming an opinion:
BMRN does not pay a dividend.
BIOMARIN PHARMACEUTICAL INC (BMRN) will report earnings on 2025-10-27, after the market close.
The PE ratio for BIOMARIN PHARMACEUTICAL INC (BMRN) is 17.14. This is based on the reported non-GAAP earnings per share of 3.37 and the current share price of 57.77 USD. Check the full fundamental report for a full analysis of the valuation metrics for BMRN.
The outstanding short interest for BIOMARIN PHARMACEUTICAL INC (BMRN) is 2.6% of its float. Check the ownership tab for more information on the BMRN short interest.
ChartMill assigns a technical rating of 1 / 10 to BMRN. When comparing the yearly performance of all stocks, BMRN is a bad performer in the overall market: 87.34% of all stocks are doing better.
ChartMill assigns a fundamental rating of 6 / 10 to BMRN. Both the health and profitability get an excellent rating, making BMRN a very profitable company, without any liquidiy or solvency issues.
Over the last trailing twelve months BMRN reported a non-GAAP Earnings per Share(EPS) of 3.37. The EPS increased by 139.01% compared to the year before.
Industry Rank | Sector Rank | ||
---|---|---|---|
PM (TTM) | 21.45% | ||
ROA | 8.81% | ||
ROE | 10.9% | ||
Debt/Equity | 0.1 |
35 analysts have analysed BMRN and the average price target is 98.8 USD. This implies a price increase of 71.01% is expected in the next year compared to the current price of 57.77.
For the next year, analysts expect an EPS growth of 57.89% and a revenue growth 12.45% for BMRN